



AT 2200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Rajesh MANCHANDA et al.

Confirmation No.: 9728

Serial No.: 09/855,542

Examiner: Shahnaz J. Sharareh

Filed: May 16, 2001

Group Art Unit: 1617

Title: STABILIZATION OF RADIONUCLIDE-CONTAINING COMPOSITIONS

**REQUEST FOR RECONSIDERATION**

**Mail Stop AF**  
Commissioner for Patents  
P.O. Box 1450  
ALEXANDRIA, VA 22313-1450

SIR:

In response to the Final Office Action mailed March 14, 2006, it is hereby requested that the above-identified application be reconsidered for allowance.

**REMARKS**

Withdrawal of the rejections under 35 U.S.C. §112 and 35 U.S.C. §102 is respectfully acknowledged.

**The Rejection under 35 U.S.C. §103**

The rejection of claims 1-4, 6, 8-10 and 32-33 under 35 U.S.C. §103, as being obvious over Solanki (U.S. Patent No. 5,262,175) in view of Cyr (U.S. Patent No. 6,881,396) is respectfully traversed.

Applicants again urge that it would not have been obvious to combine the Solanki and Cyr teachings in the manner suggested in the Office Action.

Solanki teaches a composition and method for stabilizing a radiopharmaceutical complex using a weak oxidizing agent. The complex is a lipophilic complex labeled with Tc-99m; see, e.g., col. 1, lines 7-30, describing the types of lipophilic complexing agents. The